早产儿动脉导管未闭的治疗进展  

Progress in the treatment of patent ductus arteriosus in preterm infants

作　　者：赵颖[1] 田秀英[1] 边希云 张婉娴[1] ZHAO Ying;TIAN Xiu-ying;BIAN Xi-yun;ZHANG Wan-xian(Department of Neonatology,Tianjin Central Hospital of Gynecology and Obstetrics,Tianjin 300100,China;Central Laboratory of Tianjin Fifth Central Hospital,Tianjin Key Laboratory of Epigenetics of Organ Development of Premature Infants)

机构地区：[1]天津市中心妇产科医院新生儿科,300100 [2]天津市第五中心医院中心实验室,天津市早产儿器官发育表观遗传重点实验室

出　　处：《天津医药》2021年第1期103-107,共5页Tianjin Medical Journal

基　　金：国家自然科学基金青年科学基金项目(81901526)。

摘　　要：动脉导管未闭(PDA)是严重影响新生儿尤其是早产儿存活及生存质量的一种疾病。目前针对PDA的治疗仍存在很大争议。本文介绍了近年来关于PDA的治疗时机选择、治疗方式(内科治疗、手术结扎及预防性治疗)及药物选择(吲哚美辛、布洛芬及对乙酰氨基酚)的研究进展,并对其利弊进行分析。Patent ductus arteriosus(PDA)is a disease that seriously affects the survival and quality of neonates,especially for premature infants.The treatment of PDA,however,is still controversial.This review introduces the research progress in the treatment of timing,methods(medical treatment,surgical ligation and preventive treatment)and drug selection(indomethacin,ibuprofen and paracetamol)of PDA in recent years,and analyzes their advantages and disadvantages.

关 键 词：动脉导管未闭 吲哚美辛 布洛芬 醋氨酚 结扎术 婴儿 新生 疾病 

分 类 号：R722.1[医药卫生—儿科]